https://www.selleckchem.com/pr....oducts/chir-99021-ct
001). The median duration of fever was shorter in group A than in group B (p = 0.003). No significant differences between both groups were observed for tumour response to TACE and OS. The doxorubicin dose was significantly correlated with duration of pain, fever, and VAS score. A lower dose of doxorubicin (50 mg) was associated with fewer PES symptoms compared with 100 mg, without effects on tumour response nor OS. A lower dose of doxorubicin (50 mg) was associated with fewer PES symptoms compared with 100 mg, without eff
Like
Comment
Share
